References
- 1. CAI A, MCCLAFFERTY B, BENSON J, RAMGOBIN D, KALAYANAMITRA R, SHAHID Z, et al. COVID-19: Catastrophic Cause of Acute Lung Injury. S D Med. 2020; 73(6):252–260.
- 2. CARSANA L, SONZOGNI A, NASR A, ROSSI RS, PELLEGRINELLI A, ZERBI P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study [published online ahead of print, 2020 Jun 8]. Lancet Infect Dis. 2020;S1473-3099(20)30434-5. doi:10.1016/S1473-3099(20)30434-5.
- 3. CONNORS JM, LEVY JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020; 18(7):1559–1561. doi:10.1111/jth.14849.
- 4. ACKERMANN M, VERLEDEN SE, KUEHNEL M, HAVERICH A, WELTE T, LAENGER F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020; 383(2):120–128. doi:10.1056/NEJMoa2015432.
- 5. BILALOGLU S, APHINYANAPHONGS, JONES S, ITURRATE E, HOCHMAN J, BERGER JS. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System [published online ahead of print, 2020 Jul 20]. JAMA. 2020; e2013372. doi:10.1001/jama.2020.13372.
- 6. MIDDELDORP S, COPPENS M, VAN HAAPS TF, FOPPEN M, VLAAR AP, MULLER MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19 [published online ahead of print, 2020 May 5]. J Thromb Haemost. 2020; doi:10.1111/jth.14888. doi:10.1111/jth.14888.
- 7. LODIGIANI C, IAPICHINO G, CARENZO L, CECCONI M, FERRAZZI P, SEBASTIAN T et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020; 191:9–14. doi:10.1016/j.thromres.2020.04.024.
- 8. OXLEY TJ, MOCCO J, MAJIDI S, KELLNER CP, SHOIRAH H, SINGH IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med. 2020; 382(20):e60. doi:10.1056/NEJMc2009787.
- 9. KLOK FA, KRUIP MJHA, VAN DER MEER NJM, ARBOUS MS, GOMMERS DAMPJ, KANT KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145–147. doi:10.1016/j.thromres.2020.04.013.
- 10. LEMKE G, SILVERMAN GJ. Blood clots and TAM receptor signalling in COVID-19 pathogenesis. Nat Rev Immunol. 2020; 20(7):395–396. doi:10.1038/s41577-020-0354-x.
- 11. XIE J, COVASSIN N, FAN Z, SINGH P, GAO W, LI G, et al. Association Between Hypoxemia and Mortality in Patients With COVID-19. Mayo Clin Proc. 2020; 95(6):1138–1147. doi:10.1016/j.mayocp.2020.04.006.
- 12. LLITJOS JF, LECLERC M, CHOCHOIS C, MONSALLIER JM, RAMAKAS M, AUVRAY M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020; 18(7):1743–1746. doi:10.1111/jth.14869.
- 13. ABOU-ISMAIL MY, DIAMOND A, KAPOOR S, ARAFAH Y, NAYAK L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020; 194:101–115. doi:10.1016/j.thromres.2020.06.029.
- 14. LEMKE G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 2013; 5(11):a009076. Published 2013 Nov 1. doi:10.1101/cshperspect.a009076.
- 15. VARGA Z, FLAMMER AJ, STEIGER P, HABERECKER M, ANDERMATT R, ZINKERNAGEL AS, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi:10.1016/S0140-6736(20)30937-5.
- 16. BURSTYN-COHEN T, HEEB MJ, LEMKE G. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest. 2009; 119(10):2942–2953. doi:10.1172/JCI39325.
- 17. BOULLANGER N, El KOURI D, TROSSAERT M, TRUCHAUD F, TREWICK D, PLANCHON B. Coagulation activation in patients with an inflammatory syndrome: is there a link with acquired protein S deficiency? Blood Coagulation & Fibrinolysis: an International Journal in Haemostasis and Thrombosis. 1998 Mar; 9(2):167–171. DOI: 10.1097/00001721-199803000-00007.
- 18. STAHL CP, WIDEMAN CS, SPIRA TJ, HAFF EC, HIXON GJ, EEVATT BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood. 1993; 81(7):1801–1807.
- 19. MALIA RG, KITCHEN S, GREAVES M, PRESTON FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol. 1990; 76(1):101–107. doi:10.1111/j.1365-2141.1990.tb07843.x.
- 20. SORICE M, GRIGGI T, ARICIERI P, CIRCELLA A, D’AGOSTINO F, RANIERI M, et al. Protein S and HIV infection. The role of anticardiolipin and anti-protein S antibodies. Thromb Res. 1994; 73(3–4):165–175. doi:10.1016/0049-3848(94)90095-7.
- 21. ERBE M, RICKERTS V, BAUERSACHS RM, LINDHOFF-LAST E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost. 2003; 9(4):325–331. doi:10.1177/107602960300900408.
- 22. FEDAK KM, BERNAL A, CAPSHAW ZA, GROSS S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015; 12:14. Published 2015 Sep 30. doi:10.1186/s12982-015-0037-4.
- 23. FAN BE, CHONG VCL, CHAN SSW, LIM GH, LIM KGE, TAN GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020; 95(6):E131–E134. doi:10.1002/ajh.25774.
- 24. KONG M, ZHANG H, CAO X, MAO X, LU Z. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol Infect. 2020; 148:e139. Published 2020 Jul 9. doi:10.1017/S0950268820001557.
- 25. TWADELL SH, BAINES KJ, GRAINGE C, GIBSON PG. The Emerging Role of Neutrophil Extracellular Traps in Respiratory Disease. Chest. 2019; 156(4):774–782. doi:10.1016/j.chest.2019.06.012.
- 26. PORTO BN, STEIN RT. Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing?. Front Immunol. 2016; 7:311. Published 2016 Aug 15. doi:10.3389/fimmu.2016.00311.
- 27. PFEILER S, MASSBERG S, ENGELMANN B. Biological basis and pathological relevance of microvascular thrombosis. Thromb Res. 2014; 133 Suppl 1:S35–S37. doi:10.1016/j.thromres.2014.03.016.
- 28. ZUO Y, YALAVARTHI S, SHI H, GOCKMAN K, ZUO M, MADISON JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020; 5(11):e138999. Published 2020 Jun 4. doi:10.1172/jci.insight.138999.